TUESDAY, Jan. 12, 2021 (HealthDay Information)
Not like common pneumonia, COVID-19 pneumonia spreads like many “wildfires” all through the lungs, researchers say.
This will likely clarify why COVID-19 pneumonia lasts longer and causes extra hurt than typical pneumonia, in keeping with the researchers at Northwestern Drugs in Chicago.
The analysis group mentioned that their purpose is to make COVID-19 extra like a foul chilly.
For the research, the group analyzed immune cells from the lungs of COVID-19 pneumonia sufferers and in contrast them to cells from sufferers with pneumonia brought on by different viruses or micro organism.
Whereas different forms of pneumonia quickly infect giant areas of the lungs, COVID-19 begins in quite a few small areas of the lungs. It then makes use of the lungs’ personal immune cells to unfold throughout the lungs over many days and even weeks. That is much like how a number of wildfires unfold via a forest, the research authors defined.
As COVID-19 pneumonia slowly strikes via the lungs, it leaves broken lung tissue in its wake and contributes to the fever, low blood stress and organ injury widespread in COVID-19 sufferers, the group mentioned.
The lengthy length of COVID-19 pneumonia, quite than larger severity, could also be why it causes extra severe problems than different forms of pneumonia, in keeping with the research authors. The report was printed on-line Jan. 11 within the journal Nature.
The researchers additionally recognized immune cells — macrophages and T cells — that might be vital targets when treating extreme COVID-19 pneumonia. Macrophages sometimes defend the lungs, however will be contaminated by the brand new coronavirus and assist unfold the an infection via the lungs, the group famous in a Northwestern information launch.
In a medical trial early this 12 months, the investigators plan to check an experimental drug that targets these immune cells in COVID-19 pneumonia sufferers. The drug reduces the inflammatory response of those immune cells.
“Our objective is to make COVID-19 delicate as an alternative of extreme, making it similar to a foul chilly,” research co-author Dr. Scott Budinger mentioned within the information launch. He’s chief of pulmonary and demanding care drugs at Northwestern College Feinberg Faculty of Drugs.
Examine co-author Dr. Richard Wunderink, professor of pulmonary and demanding care drugs at Feinberg and medical director of Northwestern Drugs’s ICU, added that “this effort really represents a ‘moonshot’ in COVID-19 analysis.”
The U.S. Facilities for Illness Management and Prevention has extra on COVID-19.
SOURCE: Northwestern Drugs, information launch, Jan. 11, 2021
Copyright © 2020 HealthDay. All rights reserved.